Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?

Conclusion: Generally, a pre-existing ILD history can increase the efficacy and incidence of ICIs' adverse reactions. Therefore, ICIs should be administered with caution.PMID:38511241 | DOI:10.2217/imt-2023-0147

Source: Cancer Control - March 21, 2024 Category: Cancer & Oncology Authors: Lin Zhu Rong Gao Han Li Yahui Zheng Junling Yang Source Type: research